These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28699048)

  • 1. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F; Kremens D; Vernino S; Karabin B
    Clin Auton Res; 2017 Jul; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract]   [Full Text] [Related]  

  • 2. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D; Lew M
    Clin Auton Res; 2017 Jul; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Lew M; Kremens D
    Clin Auton Res; 2017 Jul; 27(Suppl 1):5-7. PubMed ID: 28674866
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
    Vernino S; Lew M; Kremens D
    Clin Auton Res; 2017 Jul; 27(Suppl 1):35-37. PubMed ID: 28623420
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP; Claassen D; Mehdirad A
    Clin Auton Res; 2017 Jul; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract]   [Full Text] [Related]  

  • 6. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D; Lew M; Claassen D; Goodman BP
    Clin Auton Res; 2017 Jul; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract]   [Full Text] [Related]  

  • 7. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
    Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
    Vernino S; Claassen D
    Clin Auton Res; 2017 Jul; 27(Suppl 1):33-34. PubMed ID: 28674868
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
    Mehdirad A; Karabin B; Gupta F
    Clin Auton Res; 2017 Jul; 27(Suppl 1):25-27. PubMed ID: 28634637
    [No Abstract]   [Full Text] [Related]  

  • 11. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP; Gupta F
    Clin Auton Res; 2017 Jul; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract]   [Full Text] [Related]  

  • 12. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F; Karabin B; Mehdirad A
    Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract]   [Full Text] [Related]  

  • 13. New developments in the management of neurogenic orthostatic hypotension.
    Biaggioni I
    Curr Cardiol Rep; 2014 Nov; 16(11):542. PubMed ID: 25303896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
    White WB; Hauser RA; Rowse GJ; Ziemann A; Hewitt LA
    Am J Cardiol; 2017 Apr; 119(7):1111-1115. PubMed ID: 28159196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
    Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA; Hewitt LA; Isaacson S
    J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
    Hauser RA; Heritier S; Rowse GJ; Hewitt LA; Isaacson SH
    Clin Neuropharmacol; 2016; 39(5):220-6. PubMed ID: 27332626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH; Kinter CW; Wight J; Neelam AR; Krakow D
    J Med Case Rep; 2020 Jun; 14(1):73. PubMed ID: 32560740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM
    Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
    Mathias CJ
    Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.